CN106723023A - A kind of lipid-lowering health food and preparation method thereof - Google Patents
A kind of lipid-lowering health food and preparation method thereof Download PDFInfo
- Publication number
- CN106723023A CN106723023A CN201611071954.7A CN201611071954A CN106723023A CN 106723023 A CN106723023 A CN 106723023A CN 201611071954 A CN201611071954 A CN 201611071954A CN 106723023 A CN106723023 A CN 106723023A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- extract
- extraction raffinate
- parts
- extracted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 235000013402 health food Nutrition 0.000 title claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 181
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 53
- 240000008620 Fagopyrum esculentum Species 0.000 claims abstract description 41
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 38
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 38
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 38
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 35
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 35
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 31
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 31
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims abstract description 16
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims abstract description 16
- 235000004426 flaxseed Nutrition 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 12
- 240000006240 Linum usitatissimum Species 0.000 claims abstract description 6
- 235000004431 Linum usitatissimum Nutrition 0.000 claims abstract description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract 10
- 235000009566 rice Nutrition 0.000 claims abstract 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 209
- 239000007788 liquid Substances 0.000 claims description 54
- 238000000605 extraction Methods 0.000 claims description 41
- 229940026314 red yeast rice Drugs 0.000 claims description 37
- 239000011347 resin Substances 0.000 claims description 25
- 229920005989 resin Polymers 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 6
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 5
- 229930013930 alkaloid Natural products 0.000 claims description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000219051 Fagopyrum Species 0.000 claims 12
- 239000003480 eluent Substances 0.000 claims 10
- 241000209094 Oryza Species 0.000 claims 9
- 238000009472 formulation Methods 0.000 claims 2
- 206010013786 Dry skin Diseases 0.000 claims 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 244000007021 Prunus avium Species 0.000 claims 1
- 235000010401 Prunus avium Nutrition 0.000 claims 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229930003944 flavone Natural products 0.000 claims 1
- 150000002212 flavone derivatives Chemical class 0.000 claims 1
- 235000011949 flavones Nutrition 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims 1
- 235000020985 whole grains Nutrition 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 23
- 239000003814 drug Substances 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 17
- 230000006378 damage Effects 0.000 abstract description 7
- 230000036541 health Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 5
- 230000007812 deficiency Effects 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 abstract description 3
- 231100000862 numbness Toxicity 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 240000007594 Oryza sativa Species 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 27
- 239000008187 granular material Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 12
- 102000007330 LDL Lipoproteins Human genes 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 108010028554 LDL Cholesterol Proteins 0.000 description 9
- 239000009427 jiangzhi Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 241000219780 Pueraria Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 238000011629 hyperlipidemia animal model Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 244000208874 Althaea officinalis Species 0.000 description 2
- 235000006576 Althaea officinalis Nutrition 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- -1 anthraquinone compounds Chemical class 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000001035 marshmallow Nutrition 0.000 description 2
- 229940057059 monascus purpureus Drugs 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000130270 Fagopyrum tataricum Species 0.000 description 1
- 235000014693 Fagopyrum tataricum Nutrition 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038372 Renal arteriosclerosis Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003417 liposynthetic effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种降脂保健食品及其制备方法,按质量份配比包括如下成分:荞麦提取物5~60份,决明子提取物5~50份;荷叶提取物5~50份;红曲米提取物5~50份;葛根提取物5~30份;亚麻籽超微粉1~30份;棉籽糖1~20份。本发明各原材料的组合,可兼治高血脂症的“湿、虚、痹”等,从而发挥协同作用。同时,解决了化学药物在治疗的同时因其严重的毒副作用给患者带来的健康损害的问题;避免了由于高血脂症患者往往伴有其他疾病而需要同时服用多种药物时,药物之间的相互作用可能影响药物的疗效,以及可能产生的许多不良反应和毒副作用。The invention discloses a lipid-lowering health food and a preparation method thereof, which comprises the following ingredients according to the mass ratio: 5-60 parts of buckwheat extract, 5-50 parts of cassia seed extract; 5-50 parts of lotus leaf extract; 5-50 parts of koji rice extract; 5-30 parts of kudzu root extract; 1-30 parts of linseed superfine powder; 1-20 parts of raffinose. The combination of each raw material of the present invention can also treat "dampness, deficiency and numbness" of hyperlipidemia, thereby exerting a synergistic effect. At the same time, it solves the problem that chemical drugs cause health damage to patients due to their serious side effects during treatment; avoids the need to take multiple drugs at the same time because patients with hyperlipidemia are often accompanied by other diseases. The interaction may affect the efficacy of the drug, as well as many possible adverse reactions and side effects.
Description
技术领域technical field
本发明属于医药保健领域,具体涉及一种降脂保健食品及其制备方法。The invention belongs to the field of medicine and health care, and in particular relates to a lipid-lowering health food and a preparation method thereof.
背景技术Background technique
高脂血症是指人体内血脂水平过高,可直接引起一些严重危害人体健康的疾病,如高血脂会导致肝功损伤,长期高血脂会导致脂肪肝、肝硬化。血脂在人体内形成动脉粥样硬化以后,会导致心肌功能紊乱,血管紧张素转换酶会大量激活,促使血管经常处于痉挛状态,而脑血管在硬化后内皮受损,导致破裂,形成出血性脑中风,而脑血管在栓子式血栓形成状态下淤滞,导致脑血栓和脑栓塞。高血脂还会诱发冠心病,当人体由于长期高脂血症形成动脉粥样硬化后,使冠状动脉内血流量变小、血管腔内变窄,心肌注血量减少,造成心肌缺血,导致心绞痛,形成冠心病。高血脂会危害冠状动脉,形成粥样硬化,大量酯类物质蛋白,在血浆中沉积移动,降低血液流速,并通过氧化作用酸败后沉积在动脉血管内皮上,并长期黏附在血管壁上,损害动脉血管内皮,形成动脉硬化。而肥胖伴高血脂者,由于胰岛素受体数相对减少从而产生胰岛素抵抗,易诱发糖尿病。此外,高血脂还可导致视力下降、失明,肾动脉硬化、肾功能衰竭,肢体坏死、溃烂,胆结石,胰腺炎,男性性功能障碍,老年痴呆等疾病。Hyperlipidemia refers to the high level of blood lipids in the human body, which can directly cause some diseases that seriously endanger human health. For example, hyperlipidemia can lead to liver function damage, and long-term hyperlipidemia can lead to fatty liver and cirrhosis. After blood lipids form atherosclerosis in the human body, it will lead to myocardial dysfunction, angiotensin-converting enzyme will be activated in large quantities, and the blood vessels are often in a state of spasm, and the endothelium of the cerebral blood vessels is damaged after hardening, resulting in rupture and the formation of hemorrhagic cerebral palsy. Stroke, while cerebral blood vessels stagnate in a state of embolic thrombosis, resulting in cerebral thrombosis and cerebral embolism. Hyperlipidemia can also induce coronary heart disease. When the human body forms atherosclerosis due to long-term hyperlipidemia, the blood flow in the coronary arteries becomes smaller, the vascular lumen becomes narrower, and the amount of myocardial blood injection decreases, resulting in myocardial ischemia, resulting in Angina, the formation of coronary heart disease. Hyperlipidemia will harm the coronary arteries and form atherosclerosis. A large amount of esters and proteins will deposit and move in the plasma, reduce the blood flow rate, and deposit on the arterial endothelium after rancidity through oxidation, and adhere to the blood vessel wall for a long time, damaging the arterial endothelium, forming arteriosclerosis. Obese people with hyperlipidemia, due to the relative decrease in the number of insulin receptors, develop insulin resistance and easily induce diabetes. In addition, hyperlipidemia can also cause vision loss, blindness, renal arteriosclerosis, renal failure, limb necrosis, ulceration, gallstones, pancreatitis, male sexual dysfunction, senile dementia and other diseases.
世界医学界公认高血脂是导致心脑血管疾病的元凶,而心脑血管疾病又是当今世界上威胁人类最严重的疾病之一,其发病率和死亡率已超过肿瘤性疾病而跃居世界第一。据卫生部最新统计数据显示,心血管病已成为我国城乡人群的第一位死亡原因,占我国居民死亡原因的近40%。2010年调查显示,中国成年人中高血压患病率高达33.5%,估计患病人数达到3.3亿,45万人死于高血压;高胆固醇血症患病率比2002年升高了1.3倍,高甘油三酯血症则升高了0.8倍,五分之一的中国成年人患有高甘油三酯血症。The world's medical community recognizes that hyperlipidemia is the culprit of cardiovascular and cerebrovascular diseases, and cardiovascular and cerebrovascular diseases are one of the most serious diseases threatening human beings in the world today. one. According to the latest statistical data from the Ministry of Health, cardiovascular disease has become the first cause of death among urban and rural populations in my country, accounting for nearly 40% of the causes of death in my country. According to the survey in 2010, the prevalence of hypertension among Chinese adults was as high as 33.5%, and the estimated number of patients reached 330 million, and 450,000 died of hypertension; the prevalence of hypercholesterolemia increased by 1.3 times compared with 2002, high Triglyceridemia increased by 0.8 times, and one fifth of Chinese adults suffer from hypertriglyceridemia.
目前,临床上用于降血脂的药物种类很多,但以化学药为主,作用机理明确,降脂效果确切。但是,由于高血脂症的控制和治疗需要长期用药,特别是伴有高血压等的患者甚至需要终生用药,而化学药物在治疗的同时因其严重的毒副作用给患者带来的健康损害也是显而易见的,多数都存在不同程度的肝、肾功能损害以及消化系统的刺激等。而他汀类还可引起非特异性肌肉疼痛或关节痛,严重的可致横纹肌溶解症。由于高血脂症患者往往伴有其他疾病,需要同时服用多种药物,药物之间的相互作用不仅可能影响药物的疗效,也会产生许多不良反应和毒副作用。At present, there are many types of drugs used clinically for lowering blood lipids, but chemical drugs are the main ones, with clear mechanisms of action and definite lipid-lowering effects. However, since the control and treatment of hyperlipidemia requires long-term medication, especially for patients with hypertension, etc., even life-long medication is required, and the health damage caused by chemical drugs to patients due to their serious side effects is also obvious. Most of them have different degrees of liver and kidney damage and stimulation of the digestive system. And statins can also cause non-specific muscle pain or joint pain, severe rhabdomyolysis can be caused. Because patients with hyperlipidemia are often accompanied by other diseases, they need to take multiple drugs at the same time. The interaction between drugs may not only affect the efficacy of drugs, but also produce many adverse reactions and side effects.
发明内容Contents of the invention
有鉴于此,针对化学药品在治疗的同时给患者健康带来的不可避免的损害,本发明的目的在于提供一种应用荞麦提取物、决明子提取物、荷叶提取物、红曲米提取物、葛根提取物、亚麻籽、棉籽糖等制成具有降脂功效的保健食品,本发明的目的之二在于提供所述保健食品的制备方法。In view of this, for the inevitable damage that chemical drugs bring to the health of patients during treatment, the object of the present invention is to provide a method of applying buckwheat extract, cassia seed extract, lotus leaf extract, red yeast rice extract, Pueraria root extract, flaxseed, raffinose, etc. are made into health food with lipid-lowering effect. The second purpose of the present invention is to provide a preparation method of the health food.
为实现上述发明目的,具体提供了如下的技术方案:In order to realize the above-mentioned purpose of the invention, the following technical solutions are specifically provided:
1、一种降脂保健食品,按质量份配比包括如下成分:荞麦提取物5~60份,决明子提取物5~50份;荷叶提取物5~50份;红曲米提取物5~50份;葛根提取物5~30份;亚麻籽超微粉1~30份;棉籽糖1~20份。1. A lipid-lowering health food, comprising the following ingredients in proportion by mass: 5-60 parts of buckwheat extract, 5-50 parts of cassia seed extract; 5-50 parts of lotus leaf extract; 5-50 parts of red yeast rice extract 50 parts; 5-30 parts of kudzu root extract; 1-30 parts of linseed superfine powder; 1-20 parts of raffinose.
优选的,按质量份配比包括如下成分:荞麦提取物40份,决明子提取物25份;荷叶提取物30份;红曲米提取物30份;葛根提取物20份;亚麻籽超微粉10份;棉籽糖5份。Preferably, the following ingredients are included in proportion by mass: 40 parts of buckwheat extract, 25 parts of cassia seed extract; 30 parts of lotus leaf extract; 30 parts of red yeast rice extract; 20 parts of kudzu root extract; parts; 5 parts of marshmallow.
优选的,所述荞麦提取物由甜荞麦或苦荞麦的花、叶、种子、根茎中提取得到,荞麦提取物中总黄酮含量不低于65.0%;所述决明子提取物由决明子提取得到,决明子提取物中总蒽酮含量不低于50.0%;荷叶提取物是由荷叶提取得到,荷叶提取物中总生物碱含量不低于50.0%;红曲米提取物是由红曲米提取得到,红曲米提取物中植物甾醇含量不低于30.0%;葛根提取物是由葛根提取得到,葛根提取物中葛根素含量不低于30.0%。Preferably, the buckwheat extract is extracted from the flowers, leaves, seeds, and rhizomes of sweet buckwheat or tartary buckwheat, and the total flavonoid content in the buckwheat extract is not less than 65.0%; The total anthrone content in the extract is not less than 50.0%; the lotus leaf extract is obtained from the lotus leaf extract, and the total alkaloid content in the lotus leaf extract is not less than 50.0%; the red yeast rice extract is obtained from the red yeast rice It is obtained that the content of phytosterol in the red yeast rice extract is not less than 30.0%; the pueraria root extract is obtained by extracting Pueraria root, and the content of puerarin in the pueraria root extract is not less than 30.0%.
进一步优选的,所述荞麦提取物、决明子提取物、荷叶提取物、红曲提取物、葛根提取物按如下步骤进行提取:Further preferably, the buckwheat extract, cassia seed extract, lotus leaf extract, red yeast extract, and kudzu root extract are extracted according to the following steps:
荞麦提取物的制备:取荞麦花、叶、种子或根茎,加入5~15倍质量的10~90wt%乙醇,在20~80℃温度下提取30~90分钟,重复1~3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用10%~90wt%乙醇10℃~40℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得荞麦提取物;Preparation of buckwheat extract: take buckwheat flowers, leaves, seeds or rhizomes, add 5 to 15 times the mass of 10 to 90 wt% ethanol, extract at a temperature of 20 to 80°C for 30 to 90 minutes, repeat 1 to 3 times, and combine the extractions solution, recovered ethanol to obtain residual solution I, and the residual solution was absorbed by D101 macroporous resin column, eluted with 10% to 90wt% ethanol at 10°C to 40°C, collected the eluate and separated ethanol to obtain residual liquid II, and the residual liquid II is further dried to obtain the buckwheat extract;
决明子提取物的制备:将决明子粉碎,加入5~15倍质量的10~90wt%乙醇,在20~80℃温度下提取30~90分钟,重复1~3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用10%~90wt%乙醇10℃~40℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得决明子提取物;Preparation of cassia seed extract: crush cassia seed, add 5 to 15 times the mass of 10 to 90 wt% ethanol, extract at a temperature of 20 to 80°C for 30 to 90 minutes, repeat 1 to 3 times, combine the extracts, and recover the remaining ethanol Liquid I, the remaining liquid is absorbed by D101 macroporous resin column, eluted with 10%-90wt% ethanol at 10°C-40°C, the eluate is collected and the ethanol is separated to obtain the remaining liquid II, and the remaining liquid II is further dried to obtain the cassia seed extract thing;
荷叶提取物的制备:将荷叶粉碎,加入5~15倍质量的10~90wt%乙醇,在20~85℃温度下提取30~90分钟,重复1~3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用10%~90wt%乙醇10℃~40℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得荷叶提取物;Preparation of lotus leaf extract: crush the lotus leaf, add 10-90wt% ethanol of 5-15 times the mass, extract at 20-85°C for 30-90 minutes, repeat 1-3 times, combine the extracts, and recover ethanol The residual liquid I was obtained, and the residual liquid was adsorbed by a D101 macroporous resin column, eluted with 10% to 90wt% ethanol at 10°C to 40°C, the eluate was collected and the ethanol was separated to obtain the residual liquid II, and the residual liquid II was further dried to obtain lotus leaf extract;
红曲米提取物的制备:在红曲米中加入5~15倍质量的10~90wt%乙醇,在20~80℃温度下提取30~90分钟,重复1~3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用10%~90wt%乙醇10℃~40℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得红曲米提取物;Preparation of red yeast rice extract: add 10-90wt% ethanol of 5-15 times the mass to red yeast rice, extract at 20-80°C for 30-90 minutes, repeat 1-3 times, combine the extracts, recover Ethanol to obtain the residual solution I, the residual solution is absorbed by D101 macroporous resin column, and eluted with 10% to 90wt% ethanol at 10°C to 40°C, the eluate is collected and the ethanol is separated to obtain the residual liquid II, and the residual liquid II is further dried Red Yeast Rice Extract;
葛根提取物的制备:在葛根中加入5~15倍质量的10~90wt%乙醇,在20~80℃温度下提取30~90分钟,重复1~3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用10%~90wt%乙醇10℃~40℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得葛根提取物。Preparation of kudzu root extract: add 5-15 times the mass of 10-90wt% ethanol to kudzu root, extract at 20-80°C for 30-90 minutes, repeat 1-3 times, combine extracts, recover ethanol to obtain residual liquid I, the remaining liquid is absorbed by a D101 macroporous resin column, eluted with 10% to 90 wt% ethanol at 10°C to 40°C, the eluate is collected and ethanol is separated to obtain the remaining liquid II, and the remaining liquid II is further dried to obtain the kudzu root extract .
进一步优选的,所述荞麦提取物、决明子提取物、荷叶提取物、红曲提取物、葛根提取物按如下步骤进行提取:Further preferably, the buckwheat extract, cassia seed extract, lotus leaf extract, red yeast extract, and kudzu root extract are extracted according to the following steps:
荞麦提取物的制备:取荞麦花、叶、种子或根茎,加入10倍质量的70wt%乙醇,在60℃温度下提取60分钟,重复3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用70wt%乙醇30℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得荞麦提取物;The preparation of buckwheat extract: take buckwheat flowers, leaves, seeds or rhizomes, add 10 times the mass of 70wt% ethanol, extract at a temperature of 60°C for 60 minutes, repeat 3 times, combine the extracts, reclaim the ethanol to obtain the remaining liquid I, the remaining The liquid is absorbed by a D101 macroporous resin column, eluted with 70wt% ethanol at 30°C, the eluate is collected and the ethanol is separated to obtain the residual liquid II, and the residual liquid II is further dried to obtain the buckwheat extract;
决明子提取物的制备:将决明子粉碎,加入15倍质量的80wt%乙醇,在70℃温度下提取60分钟,重复3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用80wt%乙醇30℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得决明子提取物;Preparation of cassia seed extract: crush cassia seed, add 15 times the mass of 80wt% ethanol, extract at 70°C for 60 minutes, repeat 3 times, combine the extracts, recover ethanol to obtain residual liquid I, and pass the residual liquid through D101 macroporous resin Column adsorption, eluting with 80wt% ethanol at 30°C, collecting the eluate and separating the ethanol to obtain the residual liquid II, and further drying the residual liquid II to obtain the cassia seed extract;
荷叶提取物的制备:将荷叶粉碎,加入10倍质量的60wt%乙醇,在65℃温度下提取90分钟,重复3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用65wt%乙醇30℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得荷叶提取物;Preparation of lotus leaf extract: crush the lotus leaf, add 10 times the mass of 60wt% ethanol, extract at 65°C for 90 minutes, repeat 3 times, combine the extracts, recover the ethanol to obtain the remaining liquid I, and pass the remaining liquid through D101 Pore resin column adsorption, eluting with 65wt% ethanol at 30°C, collecting the eluate and separating the ethanol to obtain the residual liquid II, and further drying the residual liquid II to obtain the lotus leaf extract;
红曲米提取物的制备:在红曲米中加入15倍质量的80wt%乙醇,在70℃温度下提取90分钟,重复3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用80wt%乙醇30℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得红曲米提取物;Preparation of red yeast rice extract: add 15 times the mass of 80wt% ethanol to red yeast rice, extract at 70°C for 90 minutes, repeat 3 times, combine the extracts, recover ethanol to obtain residual liquid I, and pass the residual liquid through D101 Adsorbed on a macroporous resin column, eluted with 80wt% ethanol at 30°C, collected the eluate and separated the ethanol to obtain the residual liquid II, and further dried the residual liquid II to obtain the red yeast rice extract;
葛根提取物的制备:在葛根中加入10倍质量的75wt%乙醇,在60℃温度下提取60分钟,重复3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用70wt%乙醇30℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得葛根提取物。Preparation of Pueraria root extract: Add 10 times the mass of 75wt% ethanol to Pueraria root, extract at 60°C for 60 minutes, repeat 3 times, combine the extracts, recover ethanol to obtain residual liquid I, and pass the residual liquid through D101 macroporous resin column Adsorbed, eluted with 70wt% ethanol at 30°C, collected the eluate and separated the ethanol to obtain the raffinate II, and further dried the raffinate II to obtain the kudzu root extract.
2、所述降脂保健食品的制备方法,其特征在于,将荞麦提取物、决明子提取物、荷叶提取物、红曲米提取物、葛根提取物、棉籽糖分别粉碎至小于120目的粉末,按重量份配比称取各提取物和棉籽糖,混合均匀,用85%乙醇、20目筛制粒,40℃干燥,干颗粒过10目筛整粒;将亚麻籽超微粉碎,按处方重量份配比称取后与干颗粒混合均匀,采用常规口服制剂的制备工艺制成适于口服的剂型。2. The preparation method of the lipid-lowering health food is characterized in that buckwheat extract, cassia seed extract, lotus leaf extract, red yeast rice extract, kudzu root extract, and raffinose are respectively pulverized into powders less than 120 mesh, Weigh the extracts and raffinose according to the proportion by weight, mix them evenly, granulate with 85% ethanol and a 20-mesh sieve, dry at 40°C, and pass the dry granules through a 10-mesh sieve for granulation; ultrafinely pulverize the flaxseed, and prepare according to the prescription The proportion by weight is weighed, mixed evenly with dry granules, and prepared into a dosage form suitable for oral administration by adopting a conventional preparation process of oral preparations.
优选的,所述剂型为散剂、颗粒剂、片剂、胶囊剂或口服液。Preferably, the dosage form is powder, granule, tablet, capsule or oral liquid.
本发明所用各原料的功效如下:The effect of each raw material used in the present invention is as follows:
(1)荞麦具有很高的营养价值和药用价值,历来作为药食兼用的作物进行种植。现代药理学研究发现,降脂作用与荞麦含有大量的生物类黄酮--芦丁有关,芦丁可以保护β-细胞RIN-m5f的胰岛素受体底物和腺苷酸活化蛋白激酶信号通路,抑制脂肪合成酶活性,降低血脂和胆固醇。荞麦麸总黄酮提取物可显著降低血清TG(甘油三酯)、TC(血清总胆固醇)和肝脏TG、TC等4个指标,从而降低血中胆固醇和患心脏病的危险。(1) Buckwheat has high nutritional value and medicinal value, and has been planted as a crop for both medicine and food. Modern pharmacological studies have found that the lipid-lowering effect is related to the large amount of bioflavonoid rutin contained in buckwheat. Rutin can protect the insulin receptor substrate and adenylate-activated protein kinase signaling pathway of β-cell RIN-m5f, inhibit Liposynthetic enzyme activity, lower blood lipids and cholesterol. Buckwheat bran total flavonoids extract can significantly reduce serum TG (triglyceride), TC (serum total cholesterol) and liver TG, TC and other four indicators, thereby reducing blood cholesterol and the risk of heart disease.
(2)决明子含有蒽醌类化合物及其衍生物,能促进肠蠕动,减少脂类在肠道停留时间,减少TG和胆固醇在肠道的吸收。决明子中含有的植物固醇具有抑制人体内总胆固醇水平升高和动脉粥样硬化斑块形成的作用。决明子还可通过抑制细胞内胆固醇的合成而发挥降脂作用。(2) Semen Cassiae contains anthraquinone compounds and their derivatives, which can promote intestinal peristalsis, reduce the residence time of lipids in the intestinal tract, and reduce the absorption of TG and cholesterol in the intestinal tract. The phytosterols contained in cassia seeds have the effect of inhibiting the increase of total cholesterol level in the human body and the formation of atherosclerotic plaque. Semen Cassiae can also lower blood lipids by inhibiting the synthesis of cholesterol in cells.
(3)荷叶生物碱对调节血脂中甘油三酯(TG)的指标有显著作用,荷叶生物碱对胰脂肪酶的抑制呈非竞争性抑制作用,从而减少人体对饮食中脂肪的水解和吸收。(3) Lotus leaf alkaloids have a significant effect on the index of regulating triglyceride (TG) in blood lipids, and lotus leaf alkaloids have a non-competitive inhibitory effect on the inhibition of pancreatic lipase, thereby reducing the body's ability to hydrolyze and digest fat in the diet. absorb.
(4)红曲米提取物不仅能降低胆固醇,而且对导致动脉硬化的低密度胆固醇有优先降低的作用。红曲中含有大量的植物甾醇—豆甾醇,它可以竞争性地抑制人体对胆固醇的吸收,有效降低血清胆固醇水平,调节血脂平衡。(4) Red yeast rice extract can not only lower cholesterol, but also have a preferential effect on lowering low-density cholesterol that causes arteriosclerosis. Red yeast rice contains a large amount of phytosterol-stigmasterol, which can competitively inhibit the body's absorption of cholesterol, effectively reduce serum cholesterol levels, and regulate blood lipid balance.
(5)人体实验表明,摄入棉籽糖可促进双歧杆菌增殖,产生短链脂肪酸,降低胆固醇,改善脂质代谢。由于人体缺少分解棉籽糖消化酶α-D-半乳糖苷酶,所以棉籽糖可不经消化吸收直接到达大肠内为双歧杆菌所利用,是双歧杆菌有效增殖因子。(5) Human experiments have shown that intake of raffinose can promote the proliferation of bifidobacteria, produce short-chain fatty acids, lower cholesterol, and improve lipid metabolism. Because the human body lacks the digestive enzyme α-D-galactosidase that decomposes raffinose, raffinose can directly reach the large intestine without being digested and absorbed, and is used by bifidobacteria. It is an effective growth factor for bifidobacteria.
(6)亚麻籽含有大量不饱和脂肪酸,能与胆固醇结合生成熔点低、易于运转、代谢和排泄的酯,改变胆固醇体内分布,减少血管壁中脂酯沉积。(6) Flaxseed contains a large amount of unsaturated fatty acids, which can combine with cholesterol to form esters with low melting point, easy to transport, metabolize and excrete, change the distribution of cholesterol in the body, and reduce the deposition of lipid esters in the blood vessel wall.
(7)葛根中的葛根素、大豆苷、大豆苷元、染料木苷等异黄酮类成分均具有抗心肌缺血、扩血管、降血脂等心血管系统药理活性。其中,葛根素能明显降低小鼠血清总胆固醇的含量,升高高密度脂蛋白的含量,降低低密度脂蛋白和极低密度脂蛋白含量,防止低密度脂蛋白过度氧化。葛根素通过以上作用减少脂肪在冠状动脉壁沉积,从而减少动脉粥样硬化的发生率。(7) Puerarin, daidzin, daidzein, genistin and other isoflavones in kudzu root all have cardiovascular system pharmacological activities such as anti-myocardial ischemia, vasodilator and blood lipid lowering. Among them, puerarin can significantly reduce the content of total cholesterol in mouse serum, increase the content of high-density lipoprotein, reduce the content of low-density lipoprotein and very low-density lipoprotein, and prevent excessive oxidation of low-density lipoprotein. Puerarin reduces the deposition of fat on the coronary artery wall through the above effects, thereby reducing the incidence of atherosclerosis.
本发明的有益效果在于:本发明公开了一种降脂保健食品及其制备方法,将中医对高血脂症的辩证施治理论用于配方设计,体现了整体、全面的预防治疗理念,如荞麦具有实肠胃、益气力、续精神的功效,可以有效改高血脂症患者的“虚证”;决明子味甘、苦,性寒,微咸,可清肝益肾,明目,利水通便;荷叶则具有清头目之风热,止眩晕,清痰的功效;红曲米具有活血化瘀,健脾消食功效,主治饮食积滞,脘腹胀满;葛根入脾、胃经,除脾胃虚热而渴。上述各味药材的组合,可兼治高血脂症的“湿、虚、痹”等,从而发挥协同作用。同时,解决了化学药物在治疗的同时因其严重的毒副作用给患者带来的健康损害的问题;避免了由于高血脂症患者往往伴有其他疾病而需要同时服用多种药物时,药物之间的相互作用可能影响药物的疗效,以及可能产生的许多不良反应和毒副作用。The beneficial effects of the present invention are: the present invention discloses a lipid-lowering health food and its preparation method, which uses the dialectical treatment theory of TCM for hyperlipidemia in formula design, embodies the overall and comprehensive concept of prevention and treatment, such as buckwheat It has the effects of strengthening the intestines and stomach, replenishing qi, and sustaining the spirit, and can effectively improve the "deficiency syndrome" of patients with hyperlipidemia; cassia seed is sweet, bitter, cold in nature, slightly salty, can clear the liver and kidney, improve eyesight, diuresis and laxative; Lotus leaf has the effect of clearing the wind and heat of the head, stopping dizziness and clearing phlegm; red yeast rice has the effect of promoting blood circulation and removing blood stasis, invigorating the spleen and eliminating food, and is mainly used to treat food stagnation and abdominal distension; kudzu root enters the spleen and stomach meridian to relieve spleen and stomach deficiency hot and thirsty. The combination of the above-mentioned medicinal materials can also treat "dampness, deficiency, and numbness" of hyperlipidemia, thereby exerting a synergistic effect. At the same time, it solves the problem that chemical drugs cause health damage to patients due to their serious side effects during treatment; avoids the need to take multiple drugs at the same time because patients with hyperlipidemia are often accompanied by other diseases. The interaction may affect the efficacy of the drug, as well as many possible adverse reactions and side effects.
具体实施方式detailed description
以下结合具体实施方式对本发明做进一步详细描述。需要说明的是,下述具体实施例仅为本发明较佳可行的实施方案,非因此局限本发明的保护范围,只要不构成冲突,本发明中的各个实施例以及各实施例中的各个特征可以相互结合,所形成的技术方案均在本发明的保护范围之内。The present invention will be further described in detail below in conjunction with specific embodiments. It should be noted that the following specific examples are only preferred implementations of the present invention, and are not intended to limit the protection scope of the present invention. As long as there is no conflict, each embodiment in the present invention and each feature in each embodiment They can be combined with each other, and the formed technical solutions are all within the protection scope of the present invention.
实施例1Example 1
一种降脂保健食品,按质量份配比包括如下成分:荞麦提取物40份,决明子提取物25份;荷叶提取物30份;红曲米提取物30份;葛根提取物20份;亚麻籽超微粉10份;棉籽糖5份。A lipid-lowering health food, comprising the following ingredients according to the mass ratio: 40 parts of buckwheat extract, 25 parts of cassia seed extract; 30 parts of lotus leaf extract; 30 parts of red yeast rice extract; 20 parts of kudzu root extract; flax 10 parts of superfine seed powder; 5 parts of raffinose.
所述荞麦提取物、决明子提取物、荷叶提取物、红曲米提取物、葛根提取物按如下方法进行制备:The buckwheat extract, cassia seed extract, lotus leaf extract, red yeast rice extract, kudzu root extract are prepared as follows:
荞麦提取物的制备:取荞麦花、叶、种子或根茎,加入10倍质量的70wt%乙醇,在60℃温度下提取60分钟,重复3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用70wt%乙醇30℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得荞麦提取物;The preparation of buckwheat extract: take buckwheat flowers, leaves, seeds or rhizomes, add 10 times the mass of 70wt% ethanol, extract at a temperature of 60°C for 60 minutes, repeat 3 times, combine the extracts, reclaim the ethanol to obtain the remaining liquid I, the remaining The liquid is absorbed by a D101 macroporous resin column, eluted with 70wt% ethanol at 30°C, the eluate is collected and the ethanol is separated to obtain the residual liquid II, and the residual liquid II is further dried to obtain the buckwheat extract;
决明子提取物的制备:将决明子粉碎,加入15倍质量的80wt%乙醇,在70℃温度下提取60分钟,重复3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用80wt%乙醇30℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得决明子提取物;Preparation of cassia seed extract: crush cassia seed, add 15 times the mass of 80wt% ethanol, extract at 70°C for 60 minutes, repeat 3 times, combine the extracts, recover ethanol to obtain residual liquid I, and pass the residual liquid through D101 macroporous resin Column adsorption, eluting with 80wt% ethanol at 30°C, collecting the eluate and separating the ethanol to obtain the residual liquid II, and further drying the residual liquid II to obtain the cassia seed extract;
荷叶提取物的制备:将荷叶粉碎,加入10倍质量的60wt%乙醇,在65℃温度下提取90分钟,重复3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用65wt%乙醇30℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得荷叶提取物;Preparation of lotus leaf extract: crush the lotus leaf, add 10 times the mass of 60wt% ethanol, extract at 65°C for 90 minutes, repeat 3 times, combine the extracts, recover the ethanol to obtain the remaining liquid I, and pass the remaining liquid through D101 Pore resin column adsorption, eluting with 65wt% ethanol at 30°C, collecting the eluate and separating the ethanol to obtain the residual liquid II, and further drying the residual liquid II to obtain the lotus leaf extract;
红曲米提取物的制备:在红曲米中加入15倍质量的80wt%乙醇,在70℃温度下提取90分钟,重复3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用80wt%乙醇30℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得红曲米提取物;Preparation of red yeast rice extract: add 15 times the mass of 80wt% ethanol to red yeast rice, extract at 70°C for 90 minutes, repeat 3 times, combine the extracts, recover ethanol to obtain residual liquid I, and pass the residual liquid through D101 Adsorbed on a macroporous resin column, eluted with 80wt% ethanol at 30°C, collected the eluate and separated the ethanol to obtain the residual liquid II, and further dried the residual liquid II to obtain the red yeast rice extract;
葛根提取物的制备:在葛根中加入10倍质量的75wt%乙醇,在60℃温度下提取60分钟,重复3次,合并提取液,回收乙醇得余液I,余液通过D101大孔树脂柱吸附,用70wt%乙醇30℃洗脱,收集洗脱液并分离出乙醇得余液II,将余液II进一步干燥得葛根提取物。Preparation of Pueraria root extract: Add 10 times the mass of 75wt% ethanol to Pueraria root, extract at 60°C for 60 minutes, repeat 3 times, combine the extracts, recover ethanol to obtain residual liquid I, and pass the residual liquid through D101 macroporous resin column Adsorbed, eluted with 70wt% ethanol at 30°C, collected the eluate and separated the ethanol to obtain the raffinate II, and further dried the raffinate II to obtain the kudzu root extract.
所述降脂保健食品的制备方法如下:将荞麦提取物、决明子提取物、荷叶提取物、红曲米提取物、葛根提取物、棉籽糖分别粉碎至小于120目的粉末,按重量份配比称取各提取物和棉籽糖,混合均匀,用85%乙醇、20目筛制粒,40℃干燥,干颗粒过10目筛整粒;将亚麻籽超微粉碎,按处方重量份配比称取后与干颗粒混合均匀、压片,每片重1.0g。The preparation method of the lipid-lowering health food is as follows: respectively pulverize buckwheat extract, cassia seed extract, lotus leaf extract, red yeast rice extract, kudzu root extract, and raffinose into powders less than 120 meshes, and mix according to parts by weight Weigh each extract and raffinose, mix them evenly, granulate with 85% ethanol and a 20-mesh sieve, dry at 40°C, and pass the dry granules through a 10-mesh sieve for granulation; ultrafinely pulverize the flaxseed, and weigh it according to the weight of the prescription After taking it, mix it with dry granules evenly, and press it into tablets, each tablet weighs 1.0g.
实施例2Example 2
(1)降脂保健食品的处方配比:荞麦提取物40份、决明子提取物25份、荷叶提取物30份、红曲米提取物30份、葛根提取物20份、亚麻籽超微粉10份、棉籽糖5份。(1) Prescription ratio of lipid-lowering health food: 40 parts of buckwheat extract, 25 parts of cassia seed extract, 30 parts of lotus leaf extract, 30 parts of red yeast rice extract, 20 parts of kudzu root extract, 10 parts of flaxseed superfine powder 5 parts, 5 parts of marshmallow.
(2)按实施例1中的提取物制备方法制备配方中的各提取物,将制得的提取物及棉籽糖分别粉碎、过120目筛,按重量份配比称取各提取物和棉籽糖,混合均匀,用85%乙醇制粒,40℃干燥,将亚麻籽超微粉碎后,按处方重量份配比称取亚麻籽超微粉,与颗粒混合均匀,用70%乙醇制粒,40℃干燥,10目筛整粒,包装,每袋3.0g,命名为荞麦降脂颗粒。(2) Prepare each extract in the formula according to the extract preparation method in Example 1, pulverize the prepared extract and raffinose respectively, pass through a 120 mesh sieve, and weigh each extract and cottonseed by weight proportioning Sugar, mixed evenly, granulated with 85% ethanol, dried at 40°C, after the flaxseed was ultrafinely pulverized, the flaxseed superfine powder was weighed according to the prescription weight ratio, mixed evenly with the granules, granulated with 70% ethanol, 40 ℃ drying, 10-mesh sieve granulation, packaging, 3.0g per bag, named buckwheat lipid-lowering granules.
应用实施例Application example
将实施例2制备的荞麦降脂颗粒进行降血脂功能动物实验The buckwheat lipid-lowering granule prepared in Example 2 was carried out in an animal experiment of blood-lipid-lowering function
选取SPF级雄性金黄地鼠随机分配成11组每组12只。分别设置空白对照组、高血脂模型组及荞麦降脂颗粒给药组(5mg/kg,10mg/kg)。空白组喂养普通饲料,其余组为实验组均喂养高脂饲料,连续给予高脂饲料4周后检测血脂中TG及LDL水平,确定造模是否成功。造模成功后空白对照组、高血脂模型组分别给予1.0ml/只蒸馏水,荞麦降脂颗粒给药组按照5mg/kg,10mg/kg给药4周,期间继续饲以高脂饲料及基础饲料,阳性对照组给予XX胶囊(10mg/kg),给药方法同荞麦颗粒组。各组在最后一次给药12h后,断头取血,分离血清,检测甘油三酯(TG)、低密度脂蛋白胆固醇(LDL)。结果如下:Select SPF grade male golden hamsters and randomly distribute them into 11 groups with 12 hamsters in each group. Set up a blank control group, a hyperlipidemia model group and a buckwheat Jiangzhi granule administration group (5 mg/kg, 10 mg/kg). The blank group was fed with common feed, and the rest of the experimental groups were fed with high-fat feed. After 4 weeks of continuous high-fat feed, the levels of TG and LDL in blood lipids were detected to determine whether the model was successful. After successful modeling, the blank control group and hyperlipidemia model group were given 1.0ml/piece of distilled water, respectively, and the buckwheat Jiangzhi granule administration group was given 5 mg/kg and 10 mg/kg for 4 weeks, during which they continued to be fed high-fat feed and basal feed , the positive control group was given XX capsules (10mg/kg), and the administration method was the same as that of the buckwheat granule group. 12 hours after the last administration in each group, blood was taken by decapitation, serum was separated, and triglyceride (TG) and low-density lipoprotein cholesterol (LDL) were detected. The result is as follows:
表1各给药组在饲以高脂饲料后第四周血脂成分LDL、TG实验结果(n=5)Each administration group of table 1 feeds with high-fat feed back the 4th week blood lipid component LDL, TG experimental result ( n=5)
注:与空白组比较:###P<0.001;与模型组比较:###P<0.01Note: Compared with the blank group: ###P<0.001; compared with the model group: ###P<0.01
表2荞麦降脂颗粒对于高血脂动物模型LDL、TG影响(n=7)Table 2 Buckwheat Jiangzhi Granules for hyperlipidemia animal model LDL, TG effects ( n=7)
注:于模型组比较,*P<0.05,**P<0.01,**P<0.001Note: Compared with the model group, *P<0.05, **P<0.01, **P<0.001
与正常组比较,##P<0.01,###P<0.001Compared with the normal group, ##P<0.01, ###P<0.001
由表1可知,在第四周处死动物后,高血脂模型组与空白组比较血清中LDL、TG均显著升高(P<0.01),提示成功建立高血脂动物模型。It can be seen from Table 1 that after the animals were sacrificed at the fourth week, the levels of LDL and TG in the serum of the hyperlipidemia model group were significantly higher than those of the blank group (P<0.01), suggesting that the hyperlipidemia animal model was successfully established.
由表1可知,各给药组在第八周处死后,高血脂模型组与空白组比较血清中LDL、TG均显著升高(P<0.01),提示本实验所建立的高血脂动物模型具有很好的稳定性。荞麦降脂颗粒(10mg/kg)与模型组比较对于血脂各成分TG和LDL的影响较为显著(P<0.05),与阳性对照药XX胶囊(10mg/kg)比较,荞麦降脂颗粒(10mg/kg)作用优于对照药。荞麦降脂颗粒(10mg/kg)具有降低TG及LDL的作用,与模型组比较具有显著性差异。As can be seen from Table 1, after each administration group was executed at the eighth week, LDL and TG in the serum of the hyperlipidemia model group were significantly increased compared with the blank group (P<0.01), suggesting that the hyperlipidemia animal model established in this experiment has Very good stability. Compared with the model group, Buckwheat Jiangzhi Granules (10mg/kg) had a significant effect on blood lipid components TG and LDL (P<0.05). Compared with the positive control drug XX Capsules (10mg/kg), Buckwheat Jiangzhi Granules (10mg/kg kg) is superior to the contrast drug. Buckwheat Jiangzhi Granules (10mg/kg) has the effect of lowering TG and LDL, which is significantly different from that of the model group.
由表1和表2可知,成功建立了金黄地鼠高血脂动物模型,这种模型更能与人类高脂饮食所致的高血脂疾病更为相似。通过给予荞麦降脂颗粒后初步实验研究结果发现荞麦降脂颗粒10mg/kg具有一定的降血脂作用,且降脂作用优于XX胶囊,提示荞麦降脂颗粒能够改善高血脂作用。It can be seen from Table 1 and Table 2 that the animal model of hyperlipidemia in golden hamsters has been successfully established, and this model is more similar to hyperlipidemia caused by high-fat diet in humans. After the administration of buckwheat Jiangzhi granules, the preliminary experimental research results found that 10 mg/kg of buckwheat Jiangzhi granules has a certain blood lipid-lowering effect, and the lipid-lowering effect is better than that of XX capsules, suggesting that buckwheat Jiangzhi granules can improve hyperlipidemia.
最后说明的是,以上优选实施例仅用以说明本发明的技术方案而非限制,尽管通过上述优选实施例已经对本发明进行了详细的描述,但本领域技术人员应当理解,可以在形式上和细节上对其作出各种各样的改变,而不偏离本发明权利要求书所限定的范围。Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that it can be described in terms of form and Various changes may be made in the details without departing from the scope of the invention defined by the claims.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611071954.7A CN106723023A (en) | 2016-11-29 | 2016-11-29 | A kind of lipid-lowering health food and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611071954.7A CN106723023A (en) | 2016-11-29 | 2016-11-29 | A kind of lipid-lowering health food and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106723023A true CN106723023A (en) | 2017-05-31 |
Family
ID=58902554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611071954.7A Pending CN106723023A (en) | 2016-11-29 | 2016-11-29 | A kind of lipid-lowering health food and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106723023A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108617957A (en) * | 2018-05-10 | 2018-10-09 | 丽睿客信息科技(北京)有限公司 | Nutraceutical with fat-reducing effect |
| CN109463743A (en) * | 2018-10-30 | 2019-03-15 | 新昌县东方剑电动车厂 | A kind of health food and preparation method thereof |
| CN110101736A (en) * | 2019-04-11 | 2019-08-09 | 华中科技大学 | It is a kind of for the cassia seed extract of hypoglycemic and its preparation and quality detecting method |
Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1200250A (en) * | 1997-05-23 | 1998-12-02 | 尤新 | Functional food for lowering blood-sugar, blood-lipid and blood-presure |
| CN101305759A (en) * | 2008-06-19 | 2008-11-19 | 成都大学 | A kind of tartary buckwheat health tea and preparation method thereof |
| CN101530558A (en) * | 2008-03-13 | 2009-09-16 | 北京天科仁祥医药科技有限公司 | Traditional Chinese medicine for lowering blood lipid |
| CN101606694A (en) * | 2008-06-19 | 2009-12-23 | 刘泳宏 | A kind of natural five-color fat-reducing hypoglycemic step-down congee and preparation method |
| CN101878833A (en) * | 2010-06-23 | 2010-11-10 | 云南龙润茶业集团有限公司 | Toxin expelling and beautifying tea and preparation method thereof |
| CN101991786A (en) * | 2009-08-28 | 2011-03-30 | 江春艳 | Formula of medicine for reducing blood fat and preparations thereof |
| CN101999430A (en) * | 2010-11-10 | 2011-04-06 | 西藏天麦力健康品有限公司 | Biscuit with blood sugar reducing and blood fat reducing functions |
| CN102335253A (en) * | 2010-07-20 | 2012-02-01 | 李萍 | Lipid-lowering fat-reducing plant extract particles |
| CN102994350A (en) * | 2012-12-21 | 2013-03-27 | 劲牌有限公司 | Preparation method of tartary buckwheat wine with function of reducing blood fat |
| CN103315216A (en) * | 2013-05-30 | 2013-09-25 | 宁国市亿邦生物科技有限公司 | Instant powder aiding blood fat reduction and preparation method thereof |
| CN103494277A (en) * | 2011-07-19 | 2014-01-08 | 江西江中制药(集团)有限责任公司 | Lipid-lowering weight-losing lotus leaf beverage and preparation method thereof |
| CN103829123A (en) * | 2014-01-09 | 2014-06-04 | 山西春阳生物科技有限公司 | Method for producing hypoglycemic hypolipemic product by using tartary buckwheat |
| CN104042684A (en) * | 2013-11-28 | 2014-09-17 | 天津天狮生物发展有限公司 | Traditional Chinese medicinal composition containing Gynostemma pentaphylla extract, and preparation method thereof |
| CN104352594A (en) * | 2014-11-26 | 2015-02-18 | 黑龙江省智诚医药科技有限公司 | A kind of Jiangzhining dispersible tablet and preparation method thereof |
| CN105211413A (en) * | 2015-09-21 | 2016-01-06 | 浙江科技学院 | A kind of bitter buckwheat monascus tea production method of lipopenicillinase of calming the nerves |
| CN105412279A (en) * | 2015-12-30 | 2016-03-23 | 天津嘉氏堂科技有限公司 | Blood-fat-reducing traditional Chinese medicine health care product |
| CN105709102A (en) * | 2016-03-28 | 2016-06-29 | 重庆沐雨健康咨询有限公司 | Herbaceous plant composition for reducing blood fat |
| CN105851807A (en) * | 2016-04-23 | 2016-08-17 | 徐月苗 | Functional food capable of lowering blood lipid and preparation method of functional food |
| CN105878801A (en) * | 2016-05-10 | 2016-08-24 | 胡铭 | Red kojic rice astaxanthin composition with blood lipid lowering effect |
| CN106492011A (en) * | 2016-11-01 | 2017-03-15 | 陈耕 | A kind of with lowering blood pressure and blood fat, the composition of effect of lowering blood sugar and preparation method thereof and drink |
-
2016
- 2016-11-29 CN CN201611071954.7A patent/CN106723023A/en active Pending
Patent Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1200250A (en) * | 1997-05-23 | 1998-12-02 | 尤新 | Functional food for lowering blood-sugar, blood-lipid and blood-presure |
| CN101530558A (en) * | 2008-03-13 | 2009-09-16 | 北京天科仁祥医药科技有限公司 | Traditional Chinese medicine for lowering blood lipid |
| CN101305759A (en) * | 2008-06-19 | 2008-11-19 | 成都大学 | A kind of tartary buckwheat health tea and preparation method thereof |
| CN101606694A (en) * | 2008-06-19 | 2009-12-23 | 刘泳宏 | A kind of natural five-color fat-reducing hypoglycemic step-down congee and preparation method |
| CN101991786A (en) * | 2009-08-28 | 2011-03-30 | 江春艳 | Formula of medicine for reducing blood fat and preparations thereof |
| CN101878833A (en) * | 2010-06-23 | 2010-11-10 | 云南龙润茶业集团有限公司 | Toxin expelling and beautifying tea and preparation method thereof |
| CN102335253A (en) * | 2010-07-20 | 2012-02-01 | 李萍 | Lipid-lowering fat-reducing plant extract particles |
| CN101999430A (en) * | 2010-11-10 | 2011-04-06 | 西藏天麦力健康品有限公司 | Biscuit with blood sugar reducing and blood fat reducing functions |
| CN103494277A (en) * | 2011-07-19 | 2014-01-08 | 江西江中制药(集团)有限责任公司 | Lipid-lowering weight-losing lotus leaf beverage and preparation method thereof |
| CN102994350A (en) * | 2012-12-21 | 2013-03-27 | 劲牌有限公司 | Preparation method of tartary buckwheat wine with function of reducing blood fat |
| CN103315216A (en) * | 2013-05-30 | 2013-09-25 | 宁国市亿邦生物科技有限公司 | Instant powder aiding blood fat reduction and preparation method thereof |
| CN104042684A (en) * | 2013-11-28 | 2014-09-17 | 天津天狮生物发展有限公司 | Traditional Chinese medicinal composition containing Gynostemma pentaphylla extract, and preparation method thereof |
| CN103829123A (en) * | 2014-01-09 | 2014-06-04 | 山西春阳生物科技有限公司 | Method for producing hypoglycemic hypolipemic product by using tartary buckwheat |
| CN104352594A (en) * | 2014-11-26 | 2015-02-18 | 黑龙江省智诚医药科技有限公司 | A kind of Jiangzhining dispersible tablet and preparation method thereof |
| CN105211413A (en) * | 2015-09-21 | 2016-01-06 | 浙江科技学院 | A kind of bitter buckwheat monascus tea production method of lipopenicillinase of calming the nerves |
| CN105412279A (en) * | 2015-12-30 | 2016-03-23 | 天津嘉氏堂科技有限公司 | Blood-fat-reducing traditional Chinese medicine health care product |
| CN105709102A (en) * | 2016-03-28 | 2016-06-29 | 重庆沐雨健康咨询有限公司 | Herbaceous plant composition for reducing blood fat |
| CN105851807A (en) * | 2016-04-23 | 2016-08-17 | 徐月苗 | Functional food capable of lowering blood lipid and preparation method of functional food |
| CN105878801A (en) * | 2016-05-10 | 2016-08-24 | 胡铭 | Red kojic rice astaxanthin composition with blood lipid lowering effect |
| CN106492011A (en) * | 2016-11-01 | 2017-03-15 | 陈耕 | A kind of with lowering blood pressure and blood fat, the composition of effect of lowering blood sugar and preparation method thereof and drink |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108617957A (en) * | 2018-05-10 | 2018-10-09 | 丽睿客信息科技(北京)有限公司 | Nutraceutical with fat-reducing effect |
| CN109463743A (en) * | 2018-10-30 | 2019-03-15 | 新昌县东方剑电动车厂 | A kind of health food and preparation method thereof |
| CN110101736A (en) * | 2019-04-11 | 2019-08-09 | 华中科技大学 | It is a kind of for the cassia seed extract of hypoglycemic and its preparation and quality detecting method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102133384B (en) | Ginger and dried orange peel composition, preparation method thereof and application of ginger and dried orange peel composition in preparation of attenuated synergistic medicaments in cancer radiotherapy and chemotherapy | |
| CN102526666B (en) | Ginger-long pepper composition of for reducing vomit caused by cancer chemotherapy and enhancing chemotherapy effect and preparation method thereof | |
| CN101612362B (en) | Complex preparation for regulating lipid and preventing and curing heart cerebrovascular diseases and preparation method thereof | |
| CN103127232A (en) | Total extract for mulberry leaf prescription as well as preparation and usage thereof | |
| CN111096416A (en) | Diet-depriving composition for weight-losing meal replacement and preparation method thereof | |
| CN102091314B (en) | Dried ginger and Evodia rutaecarpa composition, its preparation method and its use in the preparation of drugs with attenuated toxicity and enhanced efficacy in cancer radiotherapy and chemotherapy | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| CN106723023A (en) | A kind of lipid-lowering health food and preparation method thereof | |
| CN104173451B (en) | The application in blood sugar lowering medicine and health food of a kind of natural drug composition | |
| CN108785370A (en) | A kind of pharmaceutical composition for treating hyperlipemia and atherosclerosis | |
| CN101439069B (en) | Leaf extract of scutellaria chinensis, its preparation method and its application | |
| CN105878803B (en) | A kind of ginseng leaf of bamboo composition with prevention and treatment alcoholic liver injury | |
| CN121041342A (en) | A traditional Chinese medicine composition with the effect of improving arterial plaque, its preparation method and application | |
| CN103830374B (en) | The application in hyperuricemia clearly of three leaf glycolipids | |
| CN107890528A (en) | A kind of Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN103877513B (en) | Chinese herbal compound composition with blood fat reduction effect, and applications thereof | |
| CN102091313B (en) | Perilla leaf and ginger composition, its preparation method and its use in the preparation of cancer radiotherapy and chemotherapy drugs | |
| CN102631397B (en) | Traditional Chinese medicine composition for improving cerebral blood circulation and preparation method thereof | |
| CN100551396C (en) | Chinese patent medicine for treating fatty liver and preparation method thereof | |
| CN103800596A (en) | Areca fruit total phenol extractive as well as preparation method and application thereof | |
| CN108514568A (en) | The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur | |
| CN108295131B (en) | Plant extract composition with blood pressure reducing effect, preparation method and application thereof | |
| CN103784683A (en) | Traditional Chinese medicinal composition for treating obesity and preparation method and application thereof | |
| CN101011436A (en) | Medical usage of total phytosterone from achyranthes | |
| CN112089783A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
| RJ01 | Rejection of invention patent application after publication |